Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0XMXMG)
| ADC Name |
Belan-VA-I034 (4)
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
Belan-VA-I034 (4)
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
~4
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Belantamab
|
Antibody Info | ||||
| Antigen Name |
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17)
|
Antigen Info | ||||
| Payload Name |
I034
|
Payload Info | ||||
| Payload Target |
IKZF1/3
|
Target Info | ||||
| Linker Name |
MC-VA
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.0540 nM
|
|||
| In Vitro Model | Plasma cell myeloma | NCI-H929 cells | CVCL_1600 | ||
References